ストックスクリーナーアプリを入手
0.0005
28.57%
-0.0002
Paxmedica Inc (PXMD) 最新ニュース
PaxMedica, Inc. has filed an IPO in the amount of $18.4575 million. - marketscreener.com
Strategic Execution in Focus for Paxmedica Investors - AD HOC NEWS
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast - Defense World
Comparing PaxMedica (NASDAQ:PXMD) & ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Paxmedica’s PAX-101 Under the Microscope: Pipeline Progress and FDA Milestones - AD HOC NEWS
MorphoSys (NASDAQ:MOR) vs. PaxMedica (NASDAQ:PXMD) Head to Head Comparison - Defense World
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
QBIO Stock Price, News & Analysis - Stock Titan
PXMD Stock Price, News & Analysis - Stock Titan
CNBX Pharms Stock Price, News & Analysis - Stock Titan
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - Yahoo Finance
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
Tardimed Sciences Llc Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - GlobeNewswire
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA - marketscreener.com
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies By Benzinga - Investing.com UK
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission - Yahoo Finance
PaxMedica, Inc. (PXMD) stock price, news, quote and history - Yahoo Finance UK
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
PaxMedica prices stock and warrant offering at $1.30 per unit By Investing.com - Investing.com Canada
PaxMedica progresses with PAX-101 for sleeping sickness By Investing.com - Investing.com UK
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast - GlobeNewswire
PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq
Gapping stocks in Tuesday's session - ChartMill
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance
PaxMedica (NASDAQ: PXMD) Reports on Low-Dose Suramin for ASD Research - Digital Journal
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication - GlobeNewswire
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) - GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Which stocks are moving before the opening bell on Monday? - ChartMill
PaxMedica Comments on Common Stock Volatility - GlobeNewswire
PaxMedica CEO Interviewed by The BRAIN Foundation - GlobeNewswire
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - GlobeNewswire
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
PaxMedica Completes HAT-301 Registrational Trial for PAX-101 - GlobeNewswire
PaxMedica, Inc. Provides First Quarter 2023 Business - GlobeNewswire
PaxMedica Holds Meeting of Scientific Advisory Board - GlobeNewswire
These stocks are moving in today's pre-market session - ChartMill
Michael Derby Net Worth (2026) - GuruFocus
Howard J. Weisman Net Worth (2026) - GuruFocus
PaxMedica Releases 2022 Shareholder Letter - GlobeNewswire
Why Is PaxMedica (PXMD) Stock Up Today? - InvestorPlace
Top 5 most-shorted stocks as of January 2023 - Finbold
Which stocks are gapping on Friday? - ChartMill
PaxMedica (PXMD) Insider Trading Activity 2025 - MarketBeat
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results - GlobeNewswire
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer - GlobeNewswire
Best Penny Stocks To Buy Now? 4 Low Float Stocks To Watch This Week - PennyStocks.com
PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors - GlobeNewswire
PaxMedica, Inc. Provides Corporate Update After IPO - GlobeNewswire
PaxMedica (PXMD) Stock Price, News & Analysis - MarketBeat
Check out Kuvatris Therapeutics's stock price (PXMD) in real time - CNBC
PXMD IPO NewsMicro-cap neurodevelopment biotech PaxMedica relaunches $8 million IPO - renaissancecapital.com
SAHPRA grants approval to begin trial of PaxMedica’s long Covid-19 therapy - Clinical Trials Arena
PaxMedica, Inc. (PXMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
BSSP Stock Price, News & Analysis - Stock Titan
PAX-101 meaningfully improves core symptoms of autism - European Pharmaceutical Review
USRM Stock Price and Chart — OTC:USRM - TradingView
0.30%
0.07%
大文字化:
|
ボリューム (24 時間):